A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

For some leukemia patients, each hour of delayed care can be the difference between life and death. JHU's Eugene Shenderov is developing an AI algorithm to help doctors reach faster diagnoses.

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...

Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the ...

[Efficacy and Safety of the Induction Therapy with Different Doses of Anthracyclines for Patients with Newly Diagnosed Acute Promyelocytic Leukemia].

Betty Lester was a dedicated wife to her husband Wayne of 67 years. She was a loving mother and grand mother. She loved spending time with her family.

Fms-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). FLT3 internal tandem duplication (ITD) plays an important role in shaping the clinical ...

Human PBMCs, mucosal associated invariant T cells, AML (acute myelogenous leukemia), APL (acute promyelocytic leukemia), and myeloma cells, as well as lymph node and bone marrow cells. Tissue-derived ...

Researchers have identified a novel strategy for treating an aggressive form of leukemia – reprogramming the cancer cells to ...